PharosiBio

Pharos iBio is a South Korean biotechnology company specializing in AI-driven drug discovery and development for rare and intractable diseases. The company utilizes its proprietary Chemiverse platform, which integrates big data and deep learning algorithms to identify novel drug candidates and optimize lead compounds. Its lead program, PHI-101, is a small molecule FLT3 inhibitor currently in clinical trials for acute myeloid leukemia and ovarian cancer. Pharos iBio focuses on oncology and rare diseases, aiming to accelerate the R&D process through its advanced computational technologies. The company is listed on the KOSDAQ exchange and maintains a global presence with a subsidiary in the United States. By combining artificial intelligence with biological expertise, Pharos iBio seeks to address significant unmet medical needs in the global pharmaceutical market.